Amycretin vs Retatrutide
Amycretin (zenagamtide, NNC0487-0111) and Retatrutide (LY3437943) are two of the most discussed next-generation metabolic research compounds, and they share only one target. Amycretin is a single molecule acting on the GLP-1 and amylin receptors. Retatrutide is a single molecule acting on the GLP-1, GIP and glucagon receptors. This page compares them as research compounds.
| Amycretin | Retatrutide | |
|---|---|---|
| Development code | NNC0487-0111 (zenagamtide) | LY3437943 |
| Receptor targets | GLP-1 and amylin | GLP-1, GIP and glucagon |
| Molecule | One 68-amino-acid peptide: a GLP-1 analogue joined to an amylin agonist | One peptide acting on all three |
| Forms in trials | Once weekly and once-daily oral | Once weekly |
| Headline result | 24.3% at 36 weeks, placebo 1.1% (125-person early study) | TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9% (2,339 people) |
| Status | Phase 3 running since February 2026, none reported | Phase 3 reported and published |
| Peptx availability | Not stocked | UK single vials and Factory Direct kits |
- Development code
- NNC0487-0111 (zenagamtide)LY3437943
- Receptor targets
- GLP-1 and amylinGLP-1, GIP and glucagon
- Molecule
- One 68-amino-acid peptide: a GLP-1 analogue joined to an amylin agonistOne peptide acting on all three
- Forms in trials
- Once weekly and once-daily oralOnce weekly
- Headline result
- 24.3% at 36 weeks, placebo 1.1% (125-person early study)TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9% (2,339 people)
- Status
- Phase 3 running since February 2026, none reportedPhase 3 reported and published
- Peptx availability
- Not stockedUK single vials and Factory Direct kits
One shared target, two different additions
Both compounds act on the GLP-1 receptor. Retatrutide adds the GIP receptor, which it shares with tirzepatide, and the glucagon receptor, which in animal studies raises energy expenditure. It has no amylin activity.
Amycretin adds amylin instead. Amylin is a separate hormone system that acts on different brain circuits from the incretins. Until amycretin, amylin was added as a second molecule, as in cagrilintide with semaglutide. Amycretin joins the two activities in one peptide and has no GIP or glucagon activity.
What the trials show
Amycretin's largest reported figure comes from an early study published in The Lancet in 2025: 125 adults were randomised, and the highest-strength group lost an average of 24.3% of body weight at 36 weeks, against 1.1% on placebo. A phase 2 trial in type 2 diabetes, published in 2026, reported up to 14.5% at 36 weeks against 2.6% on placebo. Phase 3 trials began in February 2026 and none has reported.
Retatrutide's TRIUMPH-1 phase 3 trial, published in the New England Journal of Medicine in September 2026, enrolled 2,339 adults and reported weight reductions of 17.6%, 23.7% and 25.0% at 80 weeks, against 3.9% on placebo.
The amycretin figure comes from a small early study and the retatrutide figure from a large phase 3 trial, so the two cannot be ranked. No trial comparing them is registered.
An oral form
Amycretin is also being developed as a once-daily tablet, with a first-in-human study published in The Lancet in 2025 and a phase 3 trial registered. Retatrutide has been studied only as a once-weekly compound.
Bottom line for research labs
Amycretin and Retatrutide take different routes beyond GLP-1: amycretin adds amylin, retatrutide adds GIP and glucagon. Retatrutide has the published phase 3 record. Amycretin has striking early figures and an oral form, with phase 3 still to report. Labs studying amylin alongside a triple agonist currently work with retatrutide and a separate amylin agonist such as eloralintide or cagrilintide.